UCB and Dermira have announced topline results from their Phase 3 trial (CIMPASI-1) evaluating the safety and efficacy of Cimzia (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis.
Valeant announced positive results from a Phase 3 study of IDP-118 (halobetasol propionate and tazarotene lotion) in the treatment of plaque psoriasis.
Daily application of petroleum jelly for the first 6 months of an infant's life can provide effective protection against atopic dermatitis, equating to a cost benefit of $353 per quality-adjusted life year (QALY).
To address the lack of standardized management guidelines in the treatment of psoriasis, the National Psoriasis Foundation conducted a study among psoriasis experts in an effort to define consensus based treatment targets.
Momenta has announced their adalimumab biosimilar candidate, M923, has met its Phase 3 primary endpoint of at least 75% reduction in the Psoriasis Area and Severity Index (PASI-75) following 16 weeks of treatment.
Janssen has announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA), seeking approval of guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
Aclaris has announced positive results from its two pivotal Phase 3 trials of A-101 40% Topical Solution (A-101), a novel treatment for seborrheic keratosis (SK).
Adalimumab was associated with significantly greater improvement in psoriasis severity, regardless of body region impacted, when compared with placebo.
Having greater gut bacteria diversity may indicate a greater response to immunotherapy treatment in patients with malignant melanoma, according to new research conducted by scientists at the University of Texas MD Anderson Cancer Center.
Amgen announced that the Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded indication of Enbrel (etanercept) injection to include pediatric patients aged 4-17 years with chronic moderate-to-severe plaque psoriasis.
Electronic prescriptions are associated with a lower rate of primary nonadherence to medications compared to paper prescriptions, according to a new three-year study published in JAMA Dermatology.
Allergan has announced the availability of Juvèderm Volbella XC for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
Pfizer announced that Inflectra (infliximab-dyyb) for injection will be shipped to wholesalers in late November 2016.
This prescription-only lotion is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.
The reSURFACE 1 and 2 trials were randomized, placebo-controlled, multicenter studies designed to demonstrate the efficacy of tildrakizumab in moderate-to-severe plaque psoriasis vs. placebo and comparative drug, and to assess safety and tolerability.
Patients in the SCULPTURE extension received the same blinded maintenance treatment regimen and dose up to the end of Year 3; the study became open label in Year 4.
The trial included an active comparator arm evaluating guselkumab vs. adalimumab, which demonstrated the superiority of guselkumab for major study endpoints and through Week 48 of treatment.
Regeneron and Sanofi announced that the Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).
Janssen Biotech announced that the Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adult patients.
The Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto; Amgen) as a biosimilar to Humira (adalimumab; AbbVie) for various inflammatory diseases.
Injection of platelet-rich plasma (PRP) and hyaluronic acid (HA) is associated with a clinically visible and statistically significant improvement in aging facial skin, according to a study published online in the Journal of Cosmetic Dermatology.
A literature review of head lice treatments in the U.S. found a significant decline in the effectiveness of over-the-counter (OTC) permethrin and synergized pyrethrins (collectively pyrethroids) treatments, indicating a need for judicious use of effective treatments by clinicians.
The Food and Drug Administration has granted Orphan Drug designation to TXA127 (Tarix Orphan) for the potential treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.
The Food and Drug Administration (FDA) issued a final rule regarding over-the-counter (OTC) consumer antiseptic wash products containing certain active ingredients.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ozenoxacin 1% cream (Medimetriks) for the treatment of impetigo.
The Food and Drug Administration (FDA) has approved Erelzi (etanercept-szzs; Sandoz) injection, a biosimilar to Enbrel (etanercept; Amgen).
The Food and Drug Administration (FDA) has granted Orphan Drug designation to Regenicin's cultured skin substitute, NovaDerm, for the treatment of burns requiring skin grafting.
Increased coronary artery calcium, indicative of asymptomatic coronary atherosclerosis, is apparent in patients with psoriasis, and similar to that seen in patients with type 2 diabetes, according to a study published online in JAMA Dermatology.
A marine complex supplement is beneficial for men with thinning hair, according to a study published online August 9 in the Journal of Cosmetic Dermatology.
Alitretinoin treatment aids in normalizing expression of barrier genes and proteins in patients with chronic hand eczema (CHE), according to a study published online in the British Journal of Dermatology.
Coherus BioSciences announced topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira) biosimilar candidate, for the treatment of patients with psoriasis.
Topical cowhage provocation and skin prick testing with histamine can diagnose atopic dermatitis (AD), according to a study published online July 29 in Allergy.
For patients with hidradenitis suppurativa, adalimumab is associated with higher clinical response rates, according to a study published in the New England Journal of Medicine.
Significant improvements in patient-reported outcomes (PROs) were seen with ustekinumab vs. placebo in 3 antecedent-exposure populations of patients with psoriatic arthritis, including those with prior methotrexate and anti-tumor-necrosis factor (TNF) use, according to findings from a study published in Arthritis Care & Research.
Sage Products announced a voluntary recall of one lot of Comfort Shield Barrier Cream Cloths due to contamination with the bacteria Burkholderia cepacia.
Eczema have a serious impact on patients' quality of life and overall health, both physically and mentally, according to a report from the annual American Academy of Dermatology Summer Meeting, held from July 28 to 31 in Boston.
GlaxoSmithKline announced a recall of 13 lots of Bactroban (mupirocin) Nasal Ointment, Bactroban Ointment, and Bactroban Cream. This recall is a precautionary measure due to potential contamination during manufacturing.
Valeant announced that the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has voted 18-0 for the approval of brodalumab injection to treat adults with moderate-to-severe plaque psoriasis with conditions related to product labeling and post-marketing/risk management obligations.
The Food and Drug Administration (FDA) is investigating cases of hair loss, hair breakage, balding, itching, and rash associated with the use of WEN by Chaz Dean Cleansing Conditioner products.
The Food and Drug Administration (FDA) has approved Differin Gel (adapalene; Galderma) 0.1% for over-the-counter (OTC) treatment for acne in patients aged ≥12 years.
AbbVie will present positive data from a Phase 3 study evaluating Humira (adalimumab) in patients with moderate to severe fingernail psoriasis at the Psoriasis 2016 - 5th Congress of the Psoriasis International Network in Paris, France.
For patients with psoriasis, long-term weight loss had lasting beneficial effects on the severity of psoriasis, according to a study published in the American Society of Nutrition.
In a study published in Clinical Reviews in Allergy & Immunology, researchers found that tumor necrosis factor (TNF inhibitors appeared to have clinical benefits with regard to adverse cardiovascular events in psoriasis and/or psoriatic arthritis.
Ozenoxacin belongs to a novel generation of non-fluorinated quinolones
A patient-reported study of hormonal contraceptives has found a significantly varied effect on acne among commonly prescribed agents.
The safety and efficacy of topical minoxidil for the treatment of female pattern hair loss was supported by moderate to low quality evidence in a recent Cochrane systematic review.
Regeneron and Sanofi announced that the Phase 3 study, LIBERTY AD CHRONOS, met its primary and key secondary endpoints for dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Volbella XC for use in lip augmentation and for correction of perioral rhytids (referred to as perioral lines) in adults aged >21 years old.
Wockhardt/Morton Grove Pharmaceuticals announced the discontinuation of Lindane Lotion 1%. The Companies have decided to stop manufacturing this product as of June 2, 2016.
The FDA has accepted for review the Biologics License Application (BLA) for SB2 (Samsung Bioepis), a biosimilar candidate to Remicade (infliximab; Janssen), for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1% (Allergan) for the treatment of persistent facial erythema associated with rosacea in adults.
Mirvaso (brimonidine; Galderma) Topical Gel 0.33% is now available in a pump dispenser.
The Food and Drug Administration (FDA) has approved Ameluz (aminolevulinic acid HCl; Biofrontera) gel, in combination with photodynamic therapy using BF-RhodoLED lamp, for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.
Allergan issued a voluntary recall of two lots of Tazorac (tazarotene) Gel 0.05% due to routine stability results for one lot that were slightly below regulatory specifications for Product Concentration and Content Uniformity.
Some patients use these products on suspected skin cancers because they believe it is a convenient way to remove them.
Mission Pharmacal announced that Lycelle Head Lice Removal Kit (sodium laureth sulfate, isopropanol, citronellyl acetate, hypromellose, methyl salicylate, methylparaben, citric acid) is now available without a prescription.
Eli Lilly announced that Taltz (ixekizumab) injection is now available for the treatment of moderate-to-severe plaque psoriasis through a network of specialty pharmacies.
New findings from a study published in the American Journal of Medicine may help clinicians identify high-risk drugs and high-risk patients linked to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) in order to reduce its incidence.
Regeneron and Sanofi announced that the two Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, evaluating dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints.
Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes.
The Food and Drug Administration (FDA) has approved Inflectra (infliximab-dyyb; Celltrion) for injection, a biosimilar to Remicade (infliximab; Janssen).
Patients with Staphylococcus aureus skin and soft tissue infections took an average of 57% of their antibiotic doses after being discharged from the hospital, a new study published in Antimicrobial Agents and Chemotherapy reported.
Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Tec Labs announced the launch of Tecnu Bites & Stings Medicated Itch and Pain Relief Wipes for treating insect bites and bee stings.
Anacor Pharmaceuticals announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) of crisaborole 2% topical ointment for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
The FDA is reporting a shortage in certain presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).
Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for review their supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept).
At the American Academy of Dermatology's annual meeting, researchers presented study findings supporting the safety and efficacy of ATX-101 in reducing the appearance of a double chin.
Novartis announced late-breaking data from the CLEAR study that demonstrated Cosentyx (secukinumab) was superior to Stelara (ustekinumab) in reaching near clear skin on the PASI 90 in significantly more moderate to severe psoriasis patients at Week 52.
Celgene announced long-term safety data for Otezla (apremilast) from ongoing clinical trials at the American Academy of Dermatology's Annual Meeting.
Lilly announced positive results from two Phase 3 studies, UNCOVER-2 and UNCOVER-3, of ixekizumab for the treatment of moderate-to-severe plaque psoriasis compared to etanercept or placebo. Study findings were recently presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.
Dermatoses in pregnancy provides a challenge to dermatologists when it comes to recommending treatments that are effective yet safe to the fetus.
Galderma announced the launch of qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement indicated for hair thinning and hair loss
Allergan announced that the Food and Drug Administration (FDA) has approved Aczone Gel 7.5%, a new topical treatment for acne vulgaris in patients aged ≥12 years.
The American Academy of Dermatology has released its new "Guidelines of care for the management of acne vulgaris" that includes acne treatment recommendations for adults and adolescents.
Celltrion announced that the Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of all indications for CT-P13, a biosimilar candidate of Remicade (infliximab; Janssen Biotech).
Dr. Reddy's announced that Promius Pharma has received approval for Sernivo (betamethasone dipropionate) Spray 0.05% for the treatment of mild to moderate plaque psoriasis in patients aged ≥18 years.
Dr. Reddy's Laboratories announced that the Food and Drug Administration (FDA) has granted tentative approval for Zenavod (doxycycline) capsules for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.
Amgen announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira (adalimumab).
Valeant, in partnership with AstraZeneca, announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for brodalumab injection for patients with moderate-to-severe plaque psoriasis.
Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
The Food and Drug Administration (FDA) informed that Granulex Aerosol Spray (trypsin, balsam peru, castor oil; Mylan) has been discontinued due to market conditions.
The Food and Drug Administration (FDA) is alerting healthcare professionals about possible eye and skin injuries from exposure to laser-containing products.
The Food and Drug Administration (FDA) has proposed steps to prevent the use of sunlamp products by minors and to reduce the risk of these devices for adults.
Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Leo Pharma announced that Enstilar (calcipotriene and betamethasone dipropionate) foam has been approved for the topical treatment of plaque psoriasis in adults aged ≥18 years.
The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate; Pfizer) for the treatment of adults with moderate to severe chronic plaque psoriasis.
Celgene announced that new findings from its ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis were presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress.
The Food and Drug Administration has granted avelumab (Pfizer/Merck) Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.
Skin rashes accompanied by a fever could be indicative of serious or life-threatening illness in adults and warrant immediate medical attention, according to a lecture to be presented at the American Osteopathic Association's Annual Osteopathic Medical Conference and Exposition (OMED).
Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Psoriasis patients, regardless of disease severity, may be at an increased risk of depression, according to a study recently published in JAMA Dermatology.
The FDA has granted Orphan Drug designation to the investigational cancer immunotherapy avelumab (Pfizer/Merck) for the treatment of Merkel cell carcinoma (MCC).
The active ingredient in household vinegar was effective in preventing infections and killing bacteria present in burn wounds, a new study has found.
Trevi Therapeutics announced statistically significant results from its Phase 2/3 trial of Nalbuphine ER for the treatment of moderate to severe uremic pruritus.
Theradome announced that it has initiated one of the most comprehensive studies to date to evaluate its Theradome LH80 PRO Laser Helmet on men with thinning hair or who are showing signs of balding.
The Food and Drug Administration (FDA) has accepted for review the sBLA for Keytruda (pembrolizumab, Merck) for the first-line treatment of unresectable or metastatic melanoma patients.
The Food and Drug Administration (FDA) is warning about reports of severe allergic reactions and herpes zoster associated with the use of Picato (ingenol mebutate topical gel).
The American Academy of Dermatology has issued new recommendations regarding potentially unnecessary dermatologic tests and treatments as part of the Choosing Wisely campaign.